A Pilot Study Evaluating the Immunologic Status of Patients With HER2+ Breast Cancer
This is a pilot study to gather preliminary data on the baseline immunologic status of
patients with HER-2(+) breast cancer and to establish an immune monitoring laboratory for
future clinical trial. We will ask up to 10 patients with HER-2(+) breast cancer in stable
condition and in reasonable health to participate in this study. The study will establish
an immune monitoring for correlative studies done in patients with HER-2(+) breast cancer.
The immunologic tests that will be done are ELISpot, lymphocyte proliferation, intracellular
cytokine staining, lymphocyte immunophenotyping, and ELISA.
Time Perspective: Retrospective
Dr. Ellie Guardino MD/PhD
United States: Institutional Review Board
|Stanford University School of Medicine||Stanford, California 94305-5317|